12 week open label, multicenter, non-comparative switch study evaluating efficacy, tolerability and safety of oral ziprasidone in treatment of patients suffering from schizophrenia who have already been treated with another antipsychotic
Latest Information Update: 23 Feb 2021
At a glance
- Drugs Ziprasidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 29 Aug 2006 Status change
- 06 Nov 2005 New trial record.